LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Subscribe To Our Newsletter & Stay Updated
